Standard Preparation — Competitive Intelligence Brief

Standard Preparation (Standard Preparation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tricyclic antidepressant. Area: Psychiatry.

marketed Tricyclic antidepressant Psychiatry Small molecule

Target snapshot

Standard Preparation (Standard Preparation) — University of California, Irvine. This drug works by inhibiting the reuptake of norepinephrine, serotonin, and dopamine.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard Preparation TARGET	Standard Preparation	University of California, Irvine	marketed	Tricyclic antidepressant
Anafranil	CLOMIPRAMINE	Specgx Llc	marketed	Tricyclic Antidepressant	Sodium-dependent serotonin transporter	1989-01-01
Amoxan	AMOXAPINE	Pfizer	marketed	Tricyclic Antidepressant [EPC]	5-hydroxytryptamine receptor 2A	1980-01-01
Surmontil	TRIMIPRAMINE	Teva Womens	marketed	Tricyclic Antidepressant	Histamine H1 receptor	1979-01-01
Zonalon	DOXEPIN		marketed	Tricyclic Antidepressant	Histamine H1 receptor	1969-01-01
Triptil	PROTRIPTYLINE		marketed	Tricyclic Antidepressant	Adenosine receptor A3	1967-01-01
Aventyl	NORTRIPTYLINE		marketed	Tricyclic Antidepressant	Sodium-dependent noradrenaline transporter	1964-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tricyclic antidepressant class)

1. Nova Scotia Health Authority · 1 drug in this class
2. Radboud University Medical Center · 1 drug in this class
3. University of California, Irvine · 1 drug in this class